Emerging pharmacotherapies for diabetic macular edema

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Diabetic macular edema (DME) remains an important cause of visual loss in patients with diabetes mellitus. Although photocoagulation and intensive control of systemic metabolic factors have been reported to achieve improved outcomes in large randomized clinical trials (RCTs), some patients with DME continue to lose vision despite treatment. Pharmacotherapies for DME include locally and systemically administered agents. We review several agents that have been studied for the treatment of DME.

Original languageEnglish (US)
Article number548732
JournalExperimental diabetes research
StatePublished - 2012

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Emerging pharmacotherapies for diabetic macular edema'. Together they form a unique fingerprint.

Cite this